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Background/Aims: Chronic Obstructive Pulmonary Disease (COPD) is characterized by airway inﬂam-
mation, in which contributes to loss of lung function. Systemic inﬂammation is also a feature of COPD
contributing to many associated co-morbidities. Statins, omega-3 fatty acids (docosahexanoic acid, DHA
and eicosapentanoic acid, EPA) and lycopene have been shown to decrease systemic inﬂammation;
however their combined effects have not been investigated. This study aims to identify changes in
systemic and airway inﬂammation induced by statins alone or in combination with DHA, EPA and
lycopene in COPD.
Methods: COPD patients (n ¼ 11) received rosuvastatin (20 mg/day) for 4 weeks, then a combination of
rosuvastatin (20 mg/day), DHA and EPA (1.5 g/day) and lycopene (45 mg/day) for 8 weeks. Blood and
sputum were collected and lung function measured by spirometry at baseline, week 4 and 12. Plasma
fatty acids were measured using gas chromatography, while plasma carotenoids were analysed using
high-performance liquid chromatography. Plasma CRP and IL-6 concentrations were measured using
ELISA; and peripheral blood gene expression was measured using the nCounter™ GX Human Inﬂam-
mation Kit 2.
Results: Following the interventions, clinical characteristics and plasma IL-6 and CRP were unchanged.
Sputum neutrophil proportion and absolute count was increased and macrophage proportion decreased
by rosuvastatin (P ¼ 0.020 and P ¼ 0.015; respectively). Rosuvastatin increased LTB4R and decreased
CXCL10 and AGER gene expression in white blood cells. The addition of lycopene and omega-3 fatty acids
decreased LTB4R and increased CXCL10 to basal levels, whilst combined use of interventions increased
ALOX15 blood gene expression.
Conclusion: This study shows that rosuvastatin, omega-3 fatty acids and lycopene have some anti-
inﬂammatory effects systemically, but rosuvastatin may increase airway neutrophils, which would be
undesirable in COPD patients, warranting further investigation.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic obstructive pulmonary disease (COPD) is currently
suffered by 1.2 million Australians and is expected to rise to 2.6
million by the year 2050 [1]. COPD is primarily caused by smoking
and is most prevalent in the elderly population [2]. It is charac-
terized by airway inﬂammation, resulting in small airway remod-
elling as well as destruction of lung parenchyma, ﬁbrosis of airwaysWood).
Inc. This is an open access article uand loss of lung elasticity resulting in irreversible airﬂow obstruc-
tion [3e5]. Systemic inﬂammation and oxidative stress are also key
features of COPD [6,7].
Systemic inﬂammation involves elevated acute phase proteins,
including C-reactive protein (CRP), serum amyloid A (SAA) and
surfactant protein (SP)-D [8e10], and inﬂammatory mediators
including interleukin (IL)-6, IL-1b and tumor necrosis factor (TNF)-
a [11]. Systemic inﬂammation is thought to be the cause of many of
the co-morbidities that are related to COPD [12], such as cardio-
vascular disease, diabetes and cachexia [13]. Oxidative stress also
occurs in COPD, as reactive oxygen species (ROS) are produced by
activated inﬂammatory cells in both the airways and circulationnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of oxidative stress that are elevated in COPD, include malondial-
dehyde (MDA), 8-isoprostane, protein carbonyls and oxidised low-
density lipoprotein (oxLDL) [14e16]. COPD subjects have also been
found to generally have lower circulating levels of antioxidants,
which is an indirect marker of oxidative stress [17].
Current therapies for COPD reduce symptoms, decrease fre-
quency and severity of exacerbations as well as increasing exercise
capacity [18], yet systemic inﬂammation and/or oxidative stress
persist [19]. Interventions that are prescribed for COPD patients
include bronchodilators, corticosteroids, long-term oxygen therapy
and pulmonary rehabilitation [18]. Novel therapies targeting sys-
temic inﬂammation and oxidative stress include 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or
statins, antioxidants and omega-3 fatty acids [20,21]. Previous
studies have examined the use of statins, and antioxidants indi-
vidually in COPD as well as other chronic inﬂammatory diseases,
while omega-3 fatty acids have been investigated for their anti-
inﬂammatory mechanism [20e24].
Statins have anti-inﬂammatory properties [20,25] and have
been shown to reduce markers of systemic inﬂammation including
IL-6, TNF-a and CRP in cardiovascular disease as well as animal
models of cigarette smoke exposure [26e28]. Antioxidants such as
lycopene, vitamin C and vitamin E have been previously studied in
COPD and have been shown to reduce oxidative stress and
inﬂammation [17,21,23,29]. Lycopene has been found to reduce
ROS, IL-8 and MMP-9 in THP-1 macrophages exposed to cigarette
smoke [30,31] as well as increasing antioxidant enzymes, SOD and
catalase, and decreasing inﬂammatory cytokines IL-6, TNF-a and IL-
1b in COPD patients [29]. Omega-3 fatty acids eicosapentaenoic
acid (EPA) and docosahexaenoic (DHA) have been shown to have
anti-inﬂammatory effects through inhibition of the NLRP3 inﬂam-
masome [24]. To date there are no studies that have been published
on the effects of omega-3 supplementation alone in COPD, however
a number of studies have been registered and are currently un-
derway. DHA can decrease inﬂammatory and oxidative stress
markers in mouse models of fatty liver disease and type 2 diabetes
[24,32], while the combined use of EPA and DHA in healthy par-
ticipants decreases inﬂammatory gene expression in peripheral
blood mononuclear cells (PBMCs) [33]. To date, the combined ef-
fects of statins, antioxidants and omega-3 fatty acids in COPD have
not been investigated. We hypothesised that antioxidants, statins
and omega-3 fatty acid supplementation in combination would
reduce airway and systemic inﬂammation in COPD.
2. Materials and methods
2.1. Participants
Thirteen subjects with COPD, aged 35 years and over were
recruited. COPD was deﬁned as a doctor's diagnosis as well as
having an FEV1/FVC ratio <2 standard deviations below expected
for their age, gender and height. Subjects were ex-smokers with a
smoking history of at least 10 pack years and had stopped smoking
for at least 12 months prior to commencing the study. Subjects
were excluded from the study if they had a respiratory disorder
other than COPD, had a moderate exacerbation of COPD in the
previous month or a severe exacerbation in the previous 3 months,
were receiving long-term oral corticosteroid therapy, were
currently taking statins or had any chronic disease other than
COPD.
2.2. Intervention
Subjects participated in an interventional study, of sequentialdesign, with subjects given rosuvastatin (20 mg/day) (AstraZeneca,
London, England) for the ﬁrst 4 weeks of the trial. Following this,
subjects were then given a combined intervention for 8 weeks
consisting of rosuvastatin (20 mg/day), ﬁsh oil (3 g/day; EPA
1055.1 mg, DHA 744.9 mg) (Blackmores, balgowlah, Australia) and
lycopene (45 mg/day) (LycoRed, Beer Sheva, Israel) as illustrated in
Fig. 1. Subjects completed clinic visits at weeks 0, 4 and 12. At every
visit, pulmonary function testing and St George's Respiratory
Questionnaire [34] were completed, sputum was induced and
blood samples were taken. Unused drugs and supplements were
collected at each visit to determine adherence with the interven-
tion. Participants with adherence of >80% were included in the
analysis, determined by the pill count back method [35].2.3. Clinical assessment
Pre and post bronchodilator lung function was assessed using
standardised spirometry (KoKo Spirometer, Pulmonary Data Ser-
vice, Instrumentation Inc., Louisville, USA) according to ATS rec-
ommendations [36]. Spirometric classiﬁcation of severity of COPD
was done according to GOLD criteria and based on post broncho-
dilator FEV1 as recommended by the GOLD guidelines [37].2.4. Sputum induction and processing
Sputum induction was performed with hypertonic saline (4.5%),
however 0.9% saline was substituted for subjects with FEV1<40%.
Participants inhaled nebulised saline at 30sec, 1 min, 2 min and
3  4 min intervals for a maximum time of 15.5 min. If FEV1 fell
by 15% from baseline, subjects were administered salbutamol and
the saline challenge was stopped if FEV1 did not return to within
10% of baseline. Participants were asked to produce a sputum
sample which was processed as previously described [38]. For
sputum inﬂammatory cell counts, selected sputum was dispersed
using dithiothreitol (DTT) and a total cell count and cell viability
were performed. Cytospins were prepared, stained (May-Grunwald
Giemsa) and a differential cell count obtained from 400 non-
squamous cells.2.5. Blood cholesterol analysis
Fasting blood cholesterol measurement was carried out by
Hunter Area Pathology Service (HAPS). This included total choles-
terol, LDL-cholesterol, HDL-cholesterol and triglycerides.2.6. Carotenoid assessment
High-performance liquid chromatography was used to measure
plasma carotenoid concentrations, including lycopene, a- and b-
carotene, lutein/zeaxanthin and b-cryptoxanthin [39] as previously
described [40]. Ethanol:ethyl acetate (1:1) containing an internal
standard (canthaxanthin) and butylated hydroxytoluene was
added to the sample. The solution was centrifuged (3000g, 48 C,
5 min) and the supernatant was collected, this was repeated 3
times adding ethyl acetate twice and then hexane to the pellet.
Ultrapure water was then added to the pooled supernatant ﬂuid,
and the mixture was then centrifuged. The supernatant was then
decanted and the solvents were evaporated with nitrogen. The
samplewas then reconstituted in dichloromethane:methanol (1:2).
Chromatography was performed on a hypersil ODS column with a
ﬂow rate of 0.3 mL/min, using mobile phase of acetonitrile:di-
chloromethane:methanol 0.05% ammonium acetate (85:10:5). Ca-
rotenoids were detected at 450 nm using a photodiode array.
Fig. 1. Study design for the anti-inﬂammatory intervention. Rosuvastatin (20 mg/day) was given over 12 weeks from week 0 to week 12, while ﬁsh oil (1.5 g/day) and lycopene
(45 mg/day) were given over 8 weeks from week 4 to week 12 of the study.
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Total fatty acids were measured by using the method of Lepage
and Roy [41] as previously described [42]. A methanol-to-toluene
mixture (4:1, by vol), containing C13:0 and C19:0 (0.02 g/L) and
BHT (0.12 g/L) was added to plasma. Fatty acids weremethylated by
adding acetyl chloride drop by drop while mixing by vortex, then
heating the sample to 100 C for 1 h. After cooling, the reactionwas
stopped by adding 6% K2CO3. The sample was centrifuged at 3000g
for 10 min at 4 C to facilitate the separation of layers. The upper
toluene layer was used for gas chromatography analysis of the fatty
acid methyl esters by use of a 30 m  0.25 mm fused carbon-silica
column (DB-225) that was coated with cyanopropylphenyl (J & W
Scientiﬁc, Folsom, CA). Both the injector and detector port tem-
peratures were set at 250 C. The oven temperature was initially set
at 170 C for 2 min, was increased 10 C/min until the temperature
of 190 C was reached and held for 1 min, at which point the
temperature was then increased 3 C/min until the temperature of
220 C was reached and maintained, giving a total run time of
30 min. A split ratio of 10:1 and an injection volume of 5 mL were
used. The chromatograph was equipped with a ﬂame ionization
detector, auto-sampler, and auto-detector. Sample fatty acidmethyl
ester peaks were identiﬁed by comparing their retention times
with those of a standard mixture of fatty acid methyl esters and
were quantiﬁed by using a Hewlett Packard 6890 series gas chro-
matograph with Chemstations software (version A.04.02; Palo Alto,
CA) for gas chromatographic analysis.2.8. Inﬂammatory mediator analysis
Plasma IL-6 was measured using the Human IL-6 Quantikine HS
ELISA Kit (R&D Systems, Minneapolis, Minnesota, USA) as per
manufacturer's instructions. Plasma high sensitivity CRP (hsCRP)
wasmeasured by Hunter Area Pathology Service from serummixed
withmonoclonal antibody-coated polystyrene particles, speciﬁc for
human CRP (CRP Flex reagent cartridge, Dimension Vista System,
Siemens Healthcare Diagnostics Inc. Newark USA).2.9. Gene expression analysis
RNA was extracted from whole blood using the QIAamp RNA
blood mini kit protocol as per manufacturer's instructions (Qiagen,
Hilden, Germany). Erythrocyte lysis was performed on EDTA blood
and the resulting white blood cell pellet was lysed in buffer RLT
(with 0.01% 2-mercaptoethanol) and stored at 80 C until
extraction. The column based RNA extraction was performed using
an automated QIAamp RNA blood mini kit protocol (QIAcube,
Qiagen, Hilden, Germany) with the addition of an on column DNase
digestion. After washingwith a reduced volume of RW1 buffer, RNA
bound to the QIAampmembrane was treated with DNase I. DNase I
was then removed by a second RW1 Buffer wash, washed with RPEBuffer and RNA was eluted. RNA quality and concentration was
determined using the Agilent RNA 6000 Nano Assay with the
Agilent Bioanalyser 2100. Digital expression of inﬂammatory genes
was measured using the nCounter Human Inﬂammation Kit
Version 2 (NanoString Technologies, Seattle, United States of
America), which measures the expression of 255 genes. This con-
sisted of 249 genes which are known to be differentially expressed
during inﬂammation and 6 internal reference genes (CLTC, GAPDH,
GUSB, HPRT1, PGK1 and TUBB). Digital gene expression was ana-
lysed as per manufacturer's instructions.2.10. Statistical analysis
Per protocol statistical analyses was performed in STATA IC 11
(STATA corporation, College Station, Texas, United States), using the
repeated measures ANOVA with Tukey's post-hoc test (normally
distributed data) or Friedman's test with Dunn's post-hoc test (non-
parametric data). Gene counts from the nCounter data were ﬁrst
normalised using the geometric means of the housekeeping genes
GAPDH, HPRT1 and PGK1 using the nSolver software package
provided by NanoString Technologies. The three housekeeping
genes were chosen using NormFinder as previously described [43],
this was done to determine the most stable housekeeping genes
across the samples. Genes that had mean mRNA counts of <20
across all visits were excluded due to low expression levels, genes
were also classiﬁed as nearing signiﬁcance if 0.1 > p  0.05. Para-
metric data is presented as mean ± standard error of the mean
(SEM), while non-parametric data is presented as median (quartile
1, quartile 3). Datawas assessed for normality using the D'Agostino-
Pearson omibus normality test [44]. Correlations between variables
were examined using Pearson's correlation coefﬁcient (normally
distributed data) or Spearman's correlation coefﬁcient (non-para-
metric data). P-values < 0.05 were considered statistically
signiﬁcant.
This was a pilot study aimed at determining the efﬁcacy of these
supplements in modifying inﬂammatory pathways. Hence no pri-
mary outcomewas nominated. A power calculation using any of the
classical markers of systemic inﬂammation demonstrates the study
was underpowered to detect a difference. For example, to detect a
20% change in CRP (0.6 mg/L) with SD ¼ 5 mg/L, we would require
n > 2000.2.11. Ethics
Ethics for this study was approved by Hunter New England
Health (reference number 11/02/16/3.08). The study was also
registered with the Australian New Zealand Clinical Trials Registry
(ANZCTR) e Registration number ACTRN12611000165987.
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13 participants commenced the intervention study and 2
withdrew, hence 11 participants completed the study. One of the
withdrawn patients suffered bloating on day 5 of the study and
itchiness all over by day 10, while the other withdrew from the
study due to muscle aches and pains after visit 2. The clinical
characteristics of the 11 subjects who completed the intervention at
baseline (visit 1), after statin treatment (visit 2) and after combined
statin, lycopene and ﬁsh oil treatment (visit 3) are presented in
Table 1.3.1. Clinical characteristics and blood lipids
No clinical characteristics were found to be signiﬁcantly
different between the visits, this included lung function, quality of
life, BMI and blood pressure. Total Cholesterol, LDL-Cholesterol and
Total Cholesterol/HDL ratio were decreased after statin treatment
(Table 1). No additional effect was seen with the nutritional
interventions.3.2. Nutritional biomarkers
The nutritional biomarkers including plasma fatty acids and
carotenoids are detailed in Table 2. The supplemented fatty acids,
DHA (22:5n-6) and EPA (C20:5n-3) were increased at visit 3
compared to visit 1 and 2. Saturated fatty acids, monounsaturated
fatty acids, total polyunsaturated fatty acids and total fatty acids
were all found to decrease between visits 1 and 3. Treatment in-
terventions did not signiﬁcantly change plasma carotenoid levels.
However there was a trend for increased lycopene concentration at
visit 2 and 3.Table 1
Clinical Characteristics and blood lipids at each study visit.
n ¼ 11 Visit 1
BMIb 26.5
(24.9, 27.5)
Pre FEV1%a 49.6 ± 4.0
Pre FVC%a 78.2 ± 3.8
Pre FEV1/FVCa 0.5 ± 0.0
Post FEV1%a 54.6 ± 4.5
Post FVC%a 86.5 ± 4.3
Post FEV1/FVb* 0.53
(0.37, 0.56)
Blood Pressure Systolic (mmHg)a 134.6 ± 4.9
Blood Pressure Diastolic (mmHg)a 83.3 ± 2.1
Pulse (BPM)a 78.3 ± 3.9
St. George Respiratory Questionnaire
Symptomsa 43.9 ± 6.8
Activitya 51.6 ± 7.3
Impactsa 26.3 ± 6.5
Totala 36.9 ± 6.3
Blood Cholesterol
Total Cholesterol (mmol/L)b 5.2
(4.4, 5.4)
Triglycerides (mmol/L)a 1.56 ± 0.33
LDL-Cholesterol (mmol/L)b 3.02
(2.19, 3.33)
HDL-Cholesterol (mmol/L)a 1.37 ± 0.09
Total Chol/HDL Ratiob 3.81
(3.06, 4.56)
a Data is mean ± SEM.
b Data is median (Q1, Q3).
c P < 0.05 vs V1. ‘Pre’ and ‘Post’ refer to lung function testing before and after admini3.3. Systemic inﬂammatory biomarkers
Peripheral blood and induced sputum inﬂammatory cell counts
and plasma IL-6 and CRP levels before and after each intervention
are detailed in Table 3. Peripheral blood cell counts remained
similar after the interventions, except for red blood cells which
decreased at visit 3 following the combined rosuvastatin, lycopene
and ﬁsh oil intervention (Table 3).3.4. Airway inﬂammatory biomarkers
Interestingly, the percentage and absolute counts of sputum
neutrophils were increased at visit 2 following rosuvastatin inter-
vention, however this did not reach signiﬁcance until visit 3 after
combined statin, ﬁsh oil and lycopene intervention (Table 4, Fig. 2).
The percentage of macrophages in sputum were decreased after
visit 2 after rosuvastatin intervention but this also did not reach
signiﬁcance until visit 3 following the combined statin, ﬁsh oil and
lycopene intervention (Table 4).3.5. Peripheral blood gene expression
Amongst the 255 genes that were measured, there were 5 genes
signiﬁcantly differentially expressed between the visits (Fig. 3),
with 15 genes nearing signiﬁcance (Table 5). LTB4R expression
signiﬁcantly increased after statin treatment, however LTB4R
expression subsequently decreased with the addition of ﬁsh oil and
lycopene to the treatment regimen. CXCL10 gene expression
signiﬁcantly decreased after statin treatment, but increased after
the addition of ﬁsh oil and lycopene (Fig. 3). AGER gene expression
signiﬁcantly decreased from visit 1 to visit 2 and ALOX15was found
to signiﬁcantly increase fromvisit 1 to visit 3 (Fig. 3). RIPK2was also
found to be differentially expressed during the study, howeverVisit 2 Visit 3 P-value
25.84
(24.98, 27.42)
26.05
(24.84, 27.67)
0.6297
48.64 ± 4.49 47.09 ± 4.49 0.2173
77.27 ± 3.81 75.82 ± 3.30 0.4430
0.47 ± 0.04 0.49 ± 0.03 0.5070
54.55 ± 5.05 52.64 ± 5.06 0.2575
84.18 ± 3.84 84.9 ± 4.19 0.4589
0.51
(0.37, 0.58)
0.53
(0.43, 0.60)
0.3116
136.3 ± 6.32 129.2 ± 5.87 0.3515
80.55 ± 1.88 77.73 ± 2.12 0.1118
76.09 ± 3.06 71.18 ± 4.35 0.1751
37.51 ± 7.57 41.43 ± 6.95 0.4893
50.00 ± 8.43 46.57 ± 7.97 0.3076
23.7 ± 5.66 25.14 ± 6.86 0.5113
34.04 ± 5.85 34.42 ± 6.23 0.2213
3.4
(2.7, 3.8)c
3.5
(2.7, 4.0)c
0.0010
1.19 ± 0.17 0.99 ± 0.11 0.0510
1.41
(0.89, 1.77)c
1.53
(1.06, 1.92)c
<0.001
1.47 ± 0.12 1.47 ± 0.09 0.3130
2.3
(1.99, 2.65)
2.19
(2.09, 2.53)c
<0.001
stration of bronchodilator.
Table 2
Changes in nutritional biomarkers before and after intervention.
n ¼ 11 Visit 1 Visit 2 Visit 3 P-value
Plasma Fatty Acids (mg/L)
C20:5(n-3) Eicosapentaenoic acid b 25.48 (17.36, 41.60) 24.70 (14.21, 38.33) 67.50 (43.01, 97.23)c,d <0.0001
C22:6(n-3) Docosahexaenoic acid a 61.49 ± 13.25 51.23 ± 9.01 93.10 ± 17.66c,d 0.0013
Total short chanin fatty acids b 837.2 (609.7, 1330.0) 743.5 (606.8, 1037.0) 691.8 (520.9, 1027.0)c 0.0179
Total monounsaturated fatty acids (n-3) b 729.7 (496.9, 994.2) 650.8 (510.0, 863.6) 564.0 (402.3, 813.1)d 0.0456
Total polyunsaturated fatty acids (n-6) b 916.8 (768.8, 1362.0) 749.0 (615.6, 1066.0)c 742.7 (653.2, 1187.0)c 0.0063
Total Fatty Acids b 2461.0 (1875.0, 3904.0) 2155.0 (1798.0, 2841.0) 2031.0 (1579.0, 3028.0)c 0.0179
Plasma Carotenoids (mg/L)
Lutein b 0.651 (0.28, 0.84) 0.48 (0.25, 0.85) 0.44 (0.29, 0.87) 0.6854
b-cryptoxanthin b 0.07 (0.06, 0.39) 0.11 (0.05, 0.44) 0.13 (0.08, 0.45) 0.6854
Lycopene b 0.30 (0.13, 0.54) 0.56 (0.14, 0.77) 0.50 (0.22, 0.96) 0.5690
a-carotene b 0.03 (0.01, 0.06) 0.04 (0.01, 0.07) 0.03 (0.0, 0.06) 0.5306
b-carotene a 0.25 ± 0.07 0.35 ± 0.09 0.32 ± 0.09 0.2190
Total carotenoids 1.52 ± 0.26 1.73 ± 0.30 1.97 ± 0.48 0.6559
a Data is mean ± SEM.
b Data is median (Q1, Q3).
c P < 0.05 vs 1,d P < 0.05 vs 2.
Table 3
Systemic Inﬂammation before and after intervention.
n ¼ 11 Visit 1 Visit 2 Visit 3 P-value
IL-6 pg/mL 2.2 (1.62, 3.02) 3.2 (2.3, 5.1) 3.1 (1.6, 4.8) 0.0924
CRP mg/L 3.9 (1.9, 7.9) 3.3 (0.7, 7.6) 3.8 (1.3, 8.9) 0.6862
White Cells (109/L) 5.6 (4.4, 6.3) 6.9 (4.3, 9.4) 5.8 (4.7, 6.6) 0.7064
Red Cells (1012/L) 4.6 ± 0.13 4.6 ± 0.12 4.4 ± 0.10a 0.0473
Neutrophils (109/L) 3.6 (2.5, 4.4) 4.7 (2.5, 5.7) 3.7 (2.6, 4.2) 0.1161
Lymphocytes (109/L) 1.6 (1.2, 1.9) 1.7 (1.1, 2.1) 1.7 (1.1, 2.1) 0.6317
Monocytes (109/L) 0.5 (0.4, 0.6) 0.6 (0.4, 0.8) 0.6 (0.4, 0.7) 0.1969
Eosinophils (109/L) 0.1 (0.1, 0.2) 0.1 (0.1, 0.2) 0.1 (0.1, 0.2) 0.6479
Data is median (Q1, Q3).a P < 0.05 vs V1.
Table 4
Airway Inﬂammation before and after intervention.
n ¼ 11 Visit 1 Vis
TCC (x106/mL) 4.5 (1.98, 13.95) 5
Neutrophils (%) 42.9 (24.3, 81.9) 6
Neutrophils (x104 cells/ml) 171.5 (99.8, 327.8) 27
Eosinophils (%) 0.75 (0.69, 3.09)
Eosinophils (x104 cells/ml) 3.0 (1.75, 5.5)
Macrophages (%) 50.5 (14.9, 72.4) 2
Macrophages (x104 cells/ml) 174.0 (59.5, 248.0) 10
Lymphocytes (%) 1.63 (0, 3.3) 0
Lymphocytes (x104 cells/ml) 6.5 (0, 11.25)
Data is median (Q1, Q3).a P < 0.05 vs V1.
Fig. 2. Neutrophil count and percentage in sputum. Neutrophil counts were performed o
neutrophil count (A) and percentage of neutrophils (B) in the sputum of the participants ove
increased between visits 1 and 3, suggesting that the combined use of statins, ﬁsh oil and
E.J. Williams et al. / Journal of Nutrition & Intermediary Metabolism 5 (2016) 86e9590post-hoc testing could not reveal between which visits.
Correlation analysis between differentially expressed genes and
sputum and blood cell counts revealed that peripheral blood LTB4R
gene expression had a moderate positive correlation with sputum
neutrophils at baseline (Fig. 4). Change in LTB4R gene expression
had a strong positive correlation with changes in sputum neutro-
phil count (Fig. 4), and a moderate positive correlation with blood
neutrophil counts between visits 1 and 3 (Fig. 4).
Change in peripheral blood AGER gene expression had a positive
correlation with change in sputum neutrophil count, while change
in AGER gene expression had a positive correlation with change init 2 Visit 3 P-value
.94 (2.25, 12.51) 5.4 (3.42, 13.32) 0.1781
9.9 (60.8, 82.4) 62.8 (46.3, 82.1)a 0.0161
9.5 (243.3, 329.8) 251.0 (185.3, 328.3)a 0.0198
0.5 (0.5, 1.88) 1.13 (0.44, 3.69) 0.3977
2.0 (2.0, 7.5) 4.5 (1.75, 14.75) 0.3285
5.5 (15.3, 32.5) 29.25 (11.8, 47.4)a 0.0153
2.0 (61.3, 130.0) 117.0 (47.3, 189.8) 0.0542
.88 (0.25, 4.3) 0.13 (0, 1.19) 0.2906
3.5 (1.0, 8.0) 0.5 (0.0, 4.75) 0.2208
n sputum samples taken from participants during visits 1, 2 and 3. Graphs show the
r the three visits. Both neutrophil counts and percentage were found to be signiﬁcantly
lycopene increased sputum neutrophils. *P < 0.005.
Fig. 3. Genes differently expressed between visits of the intervention study. Graphs showing the mRNA counts of genes found to be changed signiﬁcantly between visits of the
study. The mRNA counts of LTB4R (A), CXCL10 (B), AGER (C), and ALOX15 (D) were determined to be differentially expressed after the treatment interventions. The expression of
LTB4R was found to be increased after statin treatment and decreased after the combined use of statins, ﬁsh oil and lycopene. CXCL10 expression was decreased by statin treatment
and increased after the combined use of statins, ﬁsh oil and lycopene. AGER was decreased by the use of statins alone. ALOX15 was found to be increased after the combined use of
statins, ﬁsh oil and lycopene. *P < 0.005.
Table 5
mRNA counts of genes, before and after intervention, found to be signiﬁcant or approaching signiﬁcance.
Gene n ¼ 11 Gene name Visit 1 Visit 2 Visit 3 P-value Fold change
V1:V2 V2:V3 V1:V3
LTB4R leukotriene B4 receptor 312.11 ± 22.23 378.38 ± 68.29a 329.30 ± 56.75b 0.0103 1.25 1.13 1.09
CXCL10 Chemokine ligand 10 68.25 ± 11.72 53.71 ± 27.54a 67.67 ± 33.24b 0.0176 1.23 1.30 1.06
AGER Advanced glycosylation end product (AGE) receptor. 201.53 ± 10.62 174.28 ± 51.42a 177.11 ± 37.94 0.0216 1.17 1.05 1.13
RIPK2 Receptor-interacting serine-threonine kinase 2. 340.10 ± 13.11 365.36 ± 45.94 340.43 ± 35.73 0.0377 1.08 1.07 1.01
ALOX15 Arachidonate 15-lipoxygenase. 109.19 ± 20.73 120.51 ± 94.59 146.25 ± 89.90a 0.0493 1.06 1.44 1.53
TGFB1 Transforming growth factor beta 1 1380.28 ± 34.52 1386.87 ± 115.95 1453.53 ± 97.48 0.0559 1.01 1.05 1.06
PTGDR2 Prostaglandin D2 receptor 2 164.08 ± 23.24 155.06 ± 97.72 198.54 ± 96.90 0.0618 1.08 1.51 1.32
NFE2L2 Nuclear factor erythroid 2-like 2 627.90 ± 25.73 699.56 ± 57.08 663.57 ± 65.71 0.0629 1.13 1.05 1.08
HIF1A Hypoxia inducible factor 1, alpha subunit 2112.10 ± 139.69 2355.18 ± 372.34 2237.20 ± 315.75 0.0639 1.14 1.04 1.08
TCF4 Transcription factor 4 93.85 ± 10.00 81.33 ± 33.48 98.59 ± 40.87 0.0703 1.14 1.31 1.07
MAP3K7 Mitogen-activated protein kinase kinase kinase 7 400.95 ± 13.86 385.08 ± 53.87 416.28 ± 35.53 0.0761 1.04 1.10 1.04
CCL3 Chemokine Ligand 3 214.08 ± 43.46 177.00 ± 108.36 157.82 ± 97.86 0.0828 1.25 1.24 1.23
HMGB2 High mobility group box 2 764.96 ± 36.99 861.08 ± 112.21 800.25 ± 117.19 0.0929 1.14 1.06 1.06
IFNG Interferon Gamma 56.09 ± 6.07 48.33 ± 13.42 61.23 ± 21.55 0.0929 1.07 1.31 1.13
Data is mean ± SEM, a P < 0.05 Vs 1, b P < 0.05 Vs 2; P-value is difference in mRNA counts between visits.
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Change in ALOX15 gene expression had a positive correlation
with change in blood neutrophils between those visits (Fig. 4).4. Discussion
This study examined the effect of a novel anti-inﬂammatory
intervention on systemic inﬂammation in COPD. During the studytotal cholesterol, LDL-cholesterol and the total cholesterol/HDL
ratio decreased with rosuvastatin treatment as well as combined
rosuvastatin, lycopene and ﬁsh oil intervention. These results are
expected with the use of statins and conﬁrm that participants
complied with the treatment [45]. Markers of systemic inﬂamma-
tion (plasma IL-6 and CRP) however, were found to be unchanged
throughout the course of the study. Previous studies have found
that statins have decreased IL-6 and CRP in both rats exposed to
Fig. 4. Graphs of signiﬁcant correlations between Sputum and blood neutrophil and genes signiﬁcantly changed by the anti-inﬂammatory interventions. LTB4R gene expression was
positively correlated to sputum neutrophil counts at baseline (A), while change in LTB4R expression between visits 1 and 3 of the study was positively correlated with changes in
sputum (B) and blood (C) neutrophils between visits 1 and 3. Change in AGER gene expression was positively correlated with change in sputum (D) and blood (E) neutrophil count
between visits 1 and 3, change in ALOX15 gene expression was also positively correlated to change in blood (F) neutrophils between visits 1 and 3. The correlations of A and B were
calculated using Pearson's correlation, while CeF were calculated using Spearman's correlation for nonparametric data.
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[27,28,46]. Previous studies have also reported that lycopene sup-
plementation (20 mg/day, 4 months) reduced plasma IL-6 in COPD
[29] and lycopene (15 mg/day for 8 weeks) reduced plasma CRP in
healthy men [47]. These previous reports do not align with the
results of this study, which suggests that neither statins, nor the
combined use of statins, ﬁsh oil and lycopene lower systemic
inﬂammation. While the current study may have been too short in
duration or underpowered to detect a change in classical markers
of systemic inﬂammation, our data provides no convincing evi-
dence of a systemic anti-inﬂammatory effect.In the current study sputum neutrophils were increased, and
sputum macrophages decreased after the combined rosuvastatin,
lycopene and ﬁsh oil treatment. The increase in sputum neutrophils
was seen with 4 weeks of rosuvastatin alone, but did not reach
statistical signiﬁcance until the end of the combined intervention. A
previous study on patients with atopic asthma also found that
giving atorvastatin (40 mg/day) along with inhaled corticosteroids
increased neutrophils and decreasedmacrophages in sputumwhen
compared to the placebo group [48]. Other in vitro studies however,
have found that the use of pravastatin, simvastatin and atorvastatin
on neutrophils isolated from blood impairs their ability to migrate
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trophils in non-eosinophilic asthma [50], and neutrophils found in
bronchoalveolar lavage ﬂuid of mice with ovalbumin induced
asthma [51]. Similarly, a number of previous studies have found
that the use of ﬁsh oil attenuates neutrophil function, including
chemotaxis [52,53]. Hence it appears likely that the increased
neutrophils observed after intervention in our study are due to the
rosuvastatin treatment. The clinical importance of this observation
requires further investigation, as an ongoing increase in neutro-
philic inﬂammation in the airways of COPD patients may have
adverse consequences in those taking rosuvastatin.
5 genes were signiﬁcantly changed between the three visits of
the intervention study. These genes included LTB4R, CXCL10, AGER,
RIPK2 and ALOX15. LTB4R is the receptor for leukotriene B4, and acts
as a neutrophil chemoattractant [54]. During the study LTB4R was
increased by statins, however the combined use of statins, ﬁsh oil
and antioxidants lowered LTB4R back to basal levels. No previous
studies have looked at LTB4R expressionwith statin treatments, but
a previous study has shown high doses of atorvastatin had no effect
on LTB4 protein levels [55], while another study found that ator-
vastatin inhibited the 5-lipoxygenase pathway involved in LTB4
production [56]. Fish oil has been shown to reduce production of
LTB4, via substitution of DHA and EPA for arachidonic acid in cell
membranes, which results in production of LTB5 instead of LTB4
[57,58]. Our study suggests that rosuvastatin increases the
expression of LTB4 receptor, thus stimulating an increase in neu-
trophils, while the addition of ﬁsh oil may have subsequently led to
a decrease in LTB4 gene expression, back to baseline levels.
CXCL10, also known as IP-10, is a chemoattractant for activated
T-lymphocytes and is produced by neutrophils [59]. CXCL10 gene
expression was decreased with statin treatment, however this
returned to basal levels with ﬁsh oil and lycopene supplementa-
tion. Previous studies have seen that the use of ﬂuvastatin and
atorvastatin reduces CXCL10 levels systemically, which supports
the results seen in the current study [60,61]. However, it is un-
knownwhy addition of lycopene and ﬁsh oil reverses this effect, as
these nutrients have previously been shown to also reduce CXCL10
[62,63].
Advanced glycation end products (AGE) are produced when
reduced sugars react with the amino groups of proteins forming
reversible Schiff bases and then amadori products, undergoing
complex reactions to become cross-linked ﬂuorescent protein de-
rivatives [64]. AGE receptor (AGER, or RAGE) has been shown to
interact with AGEs [65]. AGER is involved in the activation of a
number of inﬂammatory genes, such as NF-kB regulated pathways,
as well as being important in a number of chronic inﬂammatory
diseases [66]. AGER was found to be signiﬁcantly decreased after
treatment with rosuvastatin. Previous studies have shown that
pravastatin and simvastatin can reduce AGER [64,65], as well as
reducing NF-kB signalling suggesting a potential anti-inﬂammatory
mechanism of statins [67,68].
Receptor-interacting serine/threonine protein-kinase 2 (RIPK2)
is a caspase-recruitment domain (CARD) containing kinase [69],
and has previously been implicated in NF-kB signalling and
inducing cell death [70]. The results of this study show that statins
may increase RIPK2, while lycopene and ﬁsh oil may decrease its
expression. No previous studies have found an association with
RIPK2 and the use of statins, lycopene or ﬁsh oil. RIPK2 may be
involved in the innate immune response of neutrophils. Decreased
RIPK2 expression has been shown to result in decreased neutrophil
chemokine and cytokine expression [71]. This may explain the
differential expression of RIPK2 in this study, and its possible
relationship to the increase in airway neutrophils.
ALOX15 encodes the enzyme arachidonate 15-lipoxygenase (15-
LO), which metabolizes arachidonic acid to yield peroxidisedproducts that are then reduced, or converted enzymatically, to form
12-hydroxyeicosatetraeonic acid (12-HETE) [72]. 12-HETE is known
to be a potent chemoattractant for neutrophils [72]. ALOX15
expression was increased after the statins, lycopene and ﬁsh oil
intervention. No previous studies have looked at ALOX15 expression
and the use of these interventions, however one study has seen that
DHA may be a substrate for 15-LO forming neuroprotectin D1
(NPD1) [73], which exerts a negative feedback system to control
oxidative stress as well as up regulating Bcl-2 anti-apoptotic pro-
teins and inhibition of the production of pro-inﬂammatory eicos-
anoids such as prostaglandin [73]. The increase in ALOX15 may also
have contributed to the increase in neutrophils seen between visit 1
and 3, as a previous study found that knocking out ALOX15 reduced
neutrophil recruitment in an acute lung injury model in mice [72].
Several correlations were seen between the changes in the
expression of genes LTB4R and ALOX15 and the changes in the
proportion or count of neutrophils in the airways and blood be-
tween baseline and after rosuvastin/combined treatment. These
results suggest that the changes in these genes seen in the study
may be related to the increase in neutrophils seen between visit 1
and 2/3. This is expected, as both LTB4R and ALOX15 have been
previously shown to play an important role in the recruitment of
neutrophils [54,72]. As the primary change that we observed in
inﬂammation in this study was an increase in sputum neutrophils,
this suggests that the changes in expression of these genes domi-
nated the inﬂammatory changes in this study.
There are several limitations to this study. In particular, the
intervention study was a pilot study with only 11 participants.
While we have seen some important effects on neutrophilic airway
inﬂammation and associated gene changes, a larger study cohort is
required to determine whether these effects are clinically impor-
tant, particularly in light of previous studies which have found that
the use of simvastatin, lovastatin, atorvastatin and ﬂuvastatin have
been associated with reduced decline in lung function in patients
with COPD, ex-smokers and current smokers [74,75].
Another limitation of the study is the sequential study design,
which does not allow us to determine whether the effects seen
between visits 1 and 3 and visit 2 and 3 are from the combined use
of rosuvastatin, lycopene and ﬁsh oil or whether they are an effect
of long term statin use or just an effect of lycopene and ﬁsh oil
supplementation. Another potential limitation of this study was
that patients ranged frommild to severe COPD; this may play a role
in the changes seen as the effect of these treatments may vary with
disease severity. During the study, plasma DHA and EPA were
increased after supplementation, at visit 3 compared to visit 1 and
2. However, plasma lycopene was not signiﬁcantly changed be-
tween any of the visits of the study. It is unknown why this
occurred and suggests that either the participants were not
adherent, or the bioavailability of the supplement was poor.
However, the latter is unlikely, as the bioavailability of the sup-
plement used has been previously conﬁrmed [76,77]. The use of a
0.05 signiﬁcance level for the gene analysis may also be seen as a
potential limitation for this study, as there were a large number of
genes assessed for expression. A more conservative p-value could
have been used, however this would have reduced the power of the
study to detect any changes in gene expression following the in-
terventions due to our small sample size.
In summary, this study has shown that rosuvastatin, ﬁsh oil and
lycopene may have some anti-inﬂammatory effects systemically,
but rosuvastatin may also have pro-inﬂammatory effects, leading to
increased airway neutrophilic airway inﬂammation. Further
investigation of the effects of rosuvastatin on clinical outcomes in
COPD is needed. Investigation of alternative forms of statins is also
warranted, as other statin drugs may not have the same undesir-
able effect on airway inﬂammation observed with rosuvastatin.
E.J. Williams et al. / Journal of Nutrition & Intermediary Metabolism 5 (2016) 86e9594There still remains a need for alternative anti-inﬂammatory treat-
ments in COPD, hence additional studies of potential treatments is
needed.
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